APOC3 and diabetes mellitus: Our findings are novel in that they show that APOC3 silencing is not only more effective in the setting of diabetes and that the harmful effects of diabetes in the artery wall are largely mediated by APOC3, but also that APOC3 is a stronger predictor of CVD risk in individuals with diabetes.